At the capital markets day held on
Keytruda® is a PD1 inhibitor used in oncology treatment with annual sales of €13 billion. Darzalex® is a CD38 inhibitor used in the treatment of Multiple Myeloma with annual sales of €3.8 billion. Together with Xdivane™, these new biosimilar candidates form an oncology biosimilar portfolio targeting €23 billion combined in annual reference product sales, which could be launched in 2028-2029 when the respective patents expire.
With the development of Xdivane™, Xbrane has expanded its high-yield protein expression platform into mammalian cells, resulting in five recently approved patents. Xbrane will leverage this platform for the upcoming programs with the aim of getting the lowest production costs amongst competing biosimilars on the market.
“With our high-yield platform technology, experienced team, and recently established development lab, we believe we are well positioned to accelerate the development of our portfolio. The development of this oncology biosimilar portfolio poses a real opportunity for us to make a sizable difference and to improve the accessibility of critical oncology products for millions of patients world-wide,” says Martin Åmark, CEO of Xbrane
Webcast
Xbrane will host a webcast for investors, analysts, and media, where CEO Martin Åmark reasons around the strategic importance of the new oncology portfolio. The webcast is held tomorrow
https://tv.streamfabriken.com/press-conference-20211214
Participant dial in number teleconference
SE: +46850558375
US: +16467224956
© Modular Finance, source